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The role of integrins in saphenous vein 
vascular smooth muscle cell migration 
Hiroyuk i  I toh,  MD,  Peter R. Nelson, MD,  Leila Mureebe, MD,  
Arie Horowi tz ,  DSc, and K. Craig Kent, MD,  Boston, Mass. 
Purpose: Smooth muscle cell (SMC) migration is an essential feature of the intimal 
hyperplastic process that so frequently limits the patency ofvascular reconstructions. The 
purpose of this investigation was to evaluate the effect of a series of integrins, or cell 
surface receptors that mediate cellular attachment, on platelet-derived growth factor 
(PDGF) and extraceUular matrix (ECM) protein-induced migration of human SMCs. 
Methods: Immtmofluorescence staining was used to search for various integrins and 
subunits on the surface of SMCs derived from human saphenous vein. Chemotaxis and 
haptotaxis of SMCs to various matrix proteins and PDGF were assayed using a 48-well 
microchemotaxis chamber in the presence or absence of antibodies that blocked the 
function of these integrins. 
Results: Several subunits (1~1, e¢2, R5) and one integrin (Rv133) were identified in 
saphenous vein SMCs. The Igl integrin antibody inhibited chemotaxis to collagen I and 
IV, laminin, and PDGF. The or2 integrin antibody inhibited collagen I and IV, and 
laminin-induced chemotaxis. The ~5 integrin antibody had no effect on SMC migration. 
The ~vJ33 integrin antibody inhibited chemotaxis to PDGF but not to the ECM proteins. 
Conclusion: Integrins are necessary for SMC migration induced by PDGF and ECM 
proteins. The integrin or subtmits responsible for facilitating migration varies with the 
stimulant. Agonists designed to inhibit integrin function might be used to suppress SMC 
migration and suppress the formation of intimal hyperplasia. (J Vasc Surg 1997; 
25:1061-9.) 
Arterial reconstruction is an effective treatment 
for arteriosclerotic occlusive disease; however, the 
long-term patency rates of these interventions are 
not always satisfactory. 1 The leading cause of failure 
of bypass grafting, endarterectomy, and angioplasty 
is neointimal hyperplasia,  process characterized by 
smooth muscle cell (SMC) migration and prolifera- 
tion and by extracellular matrix (ECM) deposi- 
tion. 2,3 Migration of vascular SMCs from the arterial 
media to the intima is an essential feature of this 
process. Animal studies have shown that as many as 
50% of  SMCs in the hyperplastic neointima re not 
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dividing, which suggests that their presence in the 
subintimal space is related to migration. 2,4 
At the time of arterial injury, vascular SMCs are 
exposed to a plethora of migratory stimuli. We re- 
cently demonstrated that ECM proteins, including 
collagen, fibronectin, laminin, and vitronectin, are 
potent agonists for SMC migration. In fact, almost 
all of  these matrix proteins have a more profound 
effect on SMC chemotaxis than the prototypical ag- 
onist of SMC migration, platelet-derived growth fac- 
tor (PDGF). 5 
Adhesive interactions of cells to matrix proteins 
are critically important for migration. Cyclic attach- 
ment and detachment of the cell membrane to ECM 
allows the SMC to propel forward. Integrins are the 
major family of cell surface adhesion receptors that 
mediate attachment. 6 These are transmembrane pro- 
teins with an external ligand-binding domain and an 
internal cytoplasmic domain. The cytoplasmic om- 
ponent is linked via a series ofintracellular proteins to 
actin filaments. Reorganization of these actin fila- 
ments provides the shape changes that are necessary 
to allow the cell to move forward. 6,7 
Integrin proteins are heterodimers composed of 
c¢ and [3 subunits. There are 16 known R subunits 
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and 8 [3 subunits that combine to produce at least 20 
different dimers or receptors. 8 Three major integrin 
families have been identified on the basis of their [3 
subunits ([31, [32, and [33). The [32 subunit is found 
primarily in platelets, but members of [31 and [33 
subunits have been identified in arterial vascular 
SMCs. 8 
Several investigations have focused on the role of 
integrins in SMC migration after growth factor stim- 
ulation. 9-n These studies have also focused on the 
behavior of SMCs derived from arteries or cell lines. 
We postulated that integrins might also be necessary 
for migration of SMCs stimulated by ECM proteins. 
We also wished to investigate the distribution of 
integrin receptors in venous SMCs because of the 
importance of these cells in the hyperplastic process 
that follows bypass grafting. 
We chose to evaluate three integrin subunits, [31, 
0~2, and ~5, and one dimer, av[33. Although the 
findings of prior studies have been conflicting, all of 
theses proteins have been previously identified in 
arterial SMCs. 9-n Using cells derived from saphe- 
nous vein, we evaluated the importance of integrin 
receptors in migration of SMCs stimulated by vari- 
ous ECM proteins and the growth factor, PDGF. It 
is not clear whether SMCs at the time of arterial 
injury are exposed to matrix proteins in soluble or 
insoluble form. Therefore, we evaluated two differ- 
ent patterns of migration, chemotaxis and hapto- 
taxis. Chemotaxis defines directed migration toward 
a positive gradient of soluble agonist, and haptotaxis 
defines directed cellular migration toward an insolu- 
ble attractant, such as a substrate-bound matrix pro- 
tein. s The following questions were posed: (1) Are 
the [31, a2, and a5 subunits or is the c~v[33 integrin 
expressed in saphenous vein vascular SMCs? (2) Are 
these integrins or subunits necessary for SMC migra- 
tion (either haptotaxis or chemotaxis ~)induced by 
ECM proteins or PDGF? 
MATERIALS AND METHODS 
General materials 
Human recombinant PDGF-AB and BB were 
obtained from Upstate Biotechnologies Inc. (Lake 
Placid, N.Y.). Bovine fibronectin, Engelbreth- 
Holm-Swarm mouse sarcoma laminin, calf skin col- 
lagen I, human placental collagen IV, vitronectin 
from bovine plasma, bovine serum albumin, and 
the smooth muscle-specific actin immunostaining 
kit were purchased from Sigma Chemical Co. (St. 
Louis). Dulbecco's modified Eagle's medium 
(DMEM), phosphate-buffered saline solution (PBS), 
fetal bovine serum (FBS), trypsin-ethylenediamine 
tetraacetic acid, penicillin/streptomycin/amphotericin 
B solution, L-glutamine, and N-2-hyclroxyethylpipera- 
zine-N-2-ethanesulfonic acid were purchased from 
Gibco BRL Life Technologies (Gaithersburg, Md.). 
Polycarbonate 8 txm-pore membranes were obtained 
from Poretics Corp. (Livermore, Calif.). The four- 
chamber slides were purchased from Nunc Inc. (Naper- 
ville, 111.). Biotinylated goat antimouse immunoglo- 
bulin G was from Vector (Burlingame, Calif.), and 
Streptavidin-Texas Red was from Amersham (Cleve- 
land). 
Antibodies 
Mouse antihuman integrin ~2 (clone P1E6), a5 
(clone P1D6), and [~1 (clone P4C10) monoclonal 
antibodies were purchased from Gibco. Mouse anti- 
human integrin av[33 (clone LM609) monoclonal 
antibodies were purchased from Chemicon Interna- 
tional Inc. (Temecula, Calif.). 
Cell culture 
Human SMCs were harvested from explants of 
remnant portions of saphenous vein intended for 
aortocoronary orperipheral arterial bypass grafting as 
previously described) e Briefly, sections ofsaphenous 
vein were opened lengthwise, and the endothelial 
and adventitial layers were gently removed. Frag- 
ments of the medial layer were placed onto tissue 
culture plates, and outward-growing SMCs were 
harvested and subcultured. Cells were maintained at 
37 ° C and 5% CO 2 in DMEM supplemented with 
10% FBS, 25 mmol/L N-2-hydroxyethylpiperazine- 
N-2-ethanesulfonic a id, 40 U/ml  penicillin G, 40 
Ixg/ml streptomycin, 100 ng/ml amphotericin B, 
and 4.8 mmol/L L-glutamine. Cells in passages 2
through 5 were used for all experimentation. SMC 
identity was verified by immunostaining with antihu- 
man e~-actin antibody and by a characteristic hill-and- 
valley growth pattern. 
Migration assay 
SMCs were grown to confluence in 100 mm 
culture dishes and were then made quiescent by 
incubation in serum-free DMEM for 72 hours. Cells 
were then washed in PBS, harvested using 0.05% 
trypsin-ethylenediamine tetraacetic acid, and resus- 
pended in serum-free DMEM. 
Migration assays were performed for 4 hours at 
37 ° C in a 48-well microchemotaxis chamber (Neu- 
roprobe, Cabin John, Md.) with upper and lower 
wells separated by polycarbonate 8 ~m-pore mem- 
brane filters. For all assays, SMCs suspended in se- 
rum-free DMEM, coincubated with integrin anti- 
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bodies in the concentrations indicated, were seeded 
at a density of 25,000 cells/well (3000 cells/mm 2) 
into the upper well of the chamber. For evaluation of 
chemotaxis, agonists diluted in DMEM were added 
to the lower well, and for control experiments phys- 
iologic buffer diluted in DMEM was added to the 
upper well. In preparation for the haptotaxis experi- 
ments, membranes were floated on ECM proteins in 
PBS in the concentrations indicated for 48 hours at 
4 ° C. Membranes were then rinsed with PBS, air 
dried, and placed into the microchemotaxis chamber 
with the coated surface facing downward. Control 
membranes were floated on PBS alone and handled 
in the same manner. Cell suspensions and antibodies 
were then added to the upper well, and DMEM 
alone was added to the lower well of the chamber. 
On completion of the 4-hour assay, membranes were 
removed, fixed in 70% ethanol at -20°C  for 20 
minutes, and stained in hematoxylin overnight. The 
upper side of the membrane was scraped using a 
cotton swab to remove cells that had attached but 
not migrated, and the membrane was then mounted 
onto a microscope slide. Migration in each well was 
assessed by counting the number of cells in five 
independent high-power fields at 200× magnifica- 
tion. The inhibitory effect of the integrin antibodies 
was expressed as a percentage of baseline (control) 
SMC migration produced by the various growth 
factor and ECM proteins. Experiments were per- 
formed in triplicate and repeated in multiple cell 
lines. 
Attachment analysis 
Attachment assays were performed for 2 hours at 
37 ° C in a 48-well microchemotaxis chamber, with 
upper and lower wells separated by a polycarbonate 8 
Ixm-pore membranes without ECM coating. For all 
assays, SMC in serum-free DMEM, coincubated 
with integrin antibodies in the concentrations indi- 
cated, were seeded at a density of 2000 cells/well 
into the upper well of the chamber. After a 2-hour 
period the membranes were washed, fixed, and 
stained in the same manner as for the migration 
assays. Attachment was assessed by counting the 
number of cells in five independent high-power fields 
at 200× magnification. 
Inmaunofluorescence staining 
Subconfluent SMCs in 100 mm dishes were 
trypsinized and seeded onto four-chamber slides at a 
concentration of 5000 cells/era 2 (1 × 104 cells/ 
well) in media that contained 10% FBS and were 
allowed to attach overnight. SMCs were incubated in 
serum-free media for 24 hours and were then fixed 
with 2% paraformaldehyde for 15 minutes at room 
temperature. Slides were incubated overnight at 4 ° C 
with primary antibody at stated concentrations and 
were then exposed to biotinylated goat antimouse 
immunoglobulin G, followed by Streptavidin-Texas 
Red. For labeling with the civ[33 integrin antibody, 
cells after fixation were pcrmeabilized for 10 minutes 
with 0.1% Triton X-100. Fluorescence was observed 
using a Nikon diaphot microscope quipped with 
epiluminescence optics. 
Statistical analysis 
Individual experiments were performed in tripli- 
cate, and all observations were made using at least 
three separate cell lines. Values are displayed as the 
mean percentage of stimulated control + SD, and 
statistical comparisons were made using Student's 
unpaired t test with Statview software on a personal 
computer. For comparisons, p values less than 0.05 
were considered significant. Data displayed are repre- 
sentative xamples. 
RESULTS 
Immunofluorescence staining 
Antibodies raised to the various subunits and 
integrins were used to confirm the presence of these 
proteins on human saphenous vein vascular SMCs. 
Fig. 1 reveals positive results ofimmunofluorescence 
staining for integrin subunits 131, 0t2, e~5, and the 
integrin av]33. Very minimal abeling was observed 
in negative control specimens that lacked the primary 
antibody. The [31, c~2, and a5 subunits were distrib- 
uted homogeneously throughout cells, with some 
increase in the intensity of staining at the cell borders 
and in extensions or lamellipodia. Visualization of 
the etv[33 integrin required permeabilization f cells 
after fixation with Triton X-100. This was surprising 
because this antibody is raised to a peptide sequence 
on the extracellular domain of this integrin. We hy- 
pothesized that permeabilization allowed the anti- 
body to gain access to integrin proteins on the basal 
or attached portion of SMCs. This finding would 
suggest that the cxv]33 is localized to this portion of 
the cell and is not distributed throughout the cell 
membrane. 
Attachment 
We first evaluated the role of these subunits and 
integrins in SMC attachment. To accurately evaluate 
chemotaxis or haptotaxis using a microchemotaxis 
chamber, the agonist or antagonist under study must 
not alter the initial attachment of cells to the upper 
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Fig. 1. Immunofluorescence staining of integrins and subunits. SMCs were seeded onto 
plastic slides ata density of 5000 cells/era 2 in media that contained 10% FBS and were allowed 
to attach overnight. After incubation i  serum-free media for 24 hours, cells were fixed with 2% 
paraformaldehyde and then incubated for 24 hours with primary antibody to [31 (A), c~2 (B), 
c~5 (C), and c~v[33 (D). Slides were then exposed to biotinylated goat antimouse immunoglob- 
ulin G, followed by Streptavidin~Texas Red. Cells, after fixation, were permeablized with 0.1% 
Triton X-100 for 10 minutes before staining with the etv[33 integrin. 
side of the porous membrane. An effect on attach- 
ment might result in a decrease in the number of cells 
that have migrated to the bottom of the membrane, 
compared with control, that is independent ofmigra- 
tion. To evaluate attachment, cells were seeded onto 
the same polycarbonate membranes us d in the mi- 
crochemotaxis chamber, in the presence or absence 
of all four blocking antibodies. There was no influ- 
ence of any of these antibodies, used in the same 
concentrations a for the migration assays, on initial 
SMC attachment (data not shown). 
Migration 
[31 subunit. Using a microchemotaxis chamber 
and a blocking antibody to the [31 subunit, we eval- 
uated the effect of [31 inhibition on SMC chemotaxis 
and haptotaxis. The clone of mouse antihuman [31 
integrin antibody used for these studies has been 
previously shown to be inhibitory at concentrations 
of 1:1500.13 [31 integrin antibody in this concentra- 
tion produced significant inhibition of chemotaxis 
induced by the ECM proteins collagen type I (22% + 
2% of control), laminin (24% _+ 1% of control), col- 
lagen type IV (43% _+ 3% of control), and fibronectin 
(49% _+ 4% of control). This inhibitory effect was 
consistently greater for collagen type I and laminin 
compared with collagen type 1V and fibronectin (p < 
0.05 for all comparisons). No inhibition ofvitronec- 
tin-induced chemotaxis was observed (Fig. 2). The 
[31 subunit antibody also inhibited collagen type 
I-induced (33% + 4% of control), collagen type 
Iv- induced (50% _+ 2% of control), laminin-induced 
(45% + 2% of control), and fibronectin-induced 
(55% _+ 2% of control) haptotaxis; however, inhibi- 
tion of vitronectin-induced haptotaxis was not ob- 
served. Even though the effect of PDGF is mediated 
through a growth factor, not an integrin receptor, 
the [31 antibody decreased to 51% + 10% of control, 
chemotaxis nduced by PDGF-BB (Fig. 2). An inhib- 
itory effect of similar magnitude (56% -+ 4% of con- 
trol) was observed for PDGF-AB-induced chemo- 
taxis. 
To evaluate whether the effect of the [31 antibody 
or the magnitude of this effect was dependent on the 
concentration of antibody used, we repeated experi- 
ments using a tenfold greater concentration of 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 6 Itoh et al. 1065 
15° 1
g 
lOO- 
r~ 
50- 
E 
¢.) 
CNI CNIV LN FN VN PDGF-BB 
Agonists 
Fig. 2. Effect of [31 integrin antibody on SMC migration 
induced by ECM proteins and PDGF-BB. Chemotaxis of 
human SMCs incubated with collagen I (CNI; 1 b~g/ml), 
collagen IV (CNIV; 1 I*g/ml), laminin (LN; 20 ~g/ml), 
fibronectin (FN; 20 b~g/ml), vitronectin (VN; 20 I*g/ml), 
and PDGF-BB (5 ng/ml), with (hatched bar) and without 
(filled bar) antibody to the [31 subunit (dilution 1:1500). 
Results are expressed as a percentage of stimulated con- 
trol _+ SD. Experiments were performed in triplicate and 
repeated in multiple cell lines. Data from a representative 
experiment are shown. *p < 0.05"compared with control 
specimen. 
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Fig. 3. Effects of~2 integrin antibody on SMC migration 
induced by ECM proteins and PDGF-BB. Chemotaxis of 
human SMCs incubated with collagen I (CNI; 1 ~g/ml), 
collagen IV (CNIV; 1 ~g/ml), laminin (LN; 20 ~g/ml), 
fibronectin (FN; 20 ~g/ml), vitronectin (VN; 20 ~g/ml) 
and PDGF-BB (5 ng/ml), with (hatched bar) and without 
(filled bar) antibody to the R2 subunit (dilution 1:6400). 
Results are expressed asa percentage ofstimulated control +_ 
SD. Experiments were performed intriplicate and repeated in
multiple cell lines. Data from a representative experiment 
are shown. *p < 0.05 compared with control specimen. 
anti-J31 (1:150). This higher concentration of anti- 
body slightly enhanced the inhibitory effect of [31 
antibody on collagen type I-  and laminin-induced 
migration, but no effect on collagen type IV- or 
fibronectin-induced migration was observed (data 
not shown). Inhibition of vitronectin-induced mi- 
gration was not observed with higher antibody con- 
centrations. SMC migration after stimulation with 
PDGF-AB and BB was also unchanged by higher 
antibody concentration (data not shown). 
oL2 subunit. The e~2 integrin blocking antibody 
has been previously shown to be inhibitory at a dilu- 
tion of 1:6400.14 At this concentration, the ~2 anti- 
body significantly inhibited chemota,vds to collagen 
type I (60% -+ 2% of control), collagen type IV (73% 
-+ 8% of control), and laminin (68% +- 7% of con- 
trol), although these inhibitory effects were consis- 
tently less than those observed with the [31 antibody. 
No inhibition of fibronectin and vitronectin chemo- 
taxis was observed (Fig. 3). Also, migration induced 
by PDGF-AB and BB was not affected by the e~2 
integrin antibody (Fig. 3). Haptotaxis after stimula- 
tion of SMC with collagen type I (84% --- 5% of 
control), collagen type IV (80% +- 3% of control), 
and laminin (87% -+ 2% of control), but not fibronec- 
tin or vitronectin, was significantly inhibited by c~2 
integrin antibody at the same concentration. When 
the concentration of c~2 integrin antibody was in- 
creased to 1:640, the inhibitory effects on chemo- 
taxis to collagen type l and IV and to laminin were 
not enhanced (data nol~ shown). 
or5 subunit. Neither ECM protein-induced che- 
motaxis nor haptotaxis were influenced by a blocking 
antibody to the c~5 integrin at a dilution of 1:150015 
(Fig. 4). PDGF-induced SMC chemotaxis was also 
not inhibited by the a5 intcgrin antibody. Even at a 
higher concentration (1:150), the a5 integrin anti- 
body did not inhibit ECM- or PDGF-induced mi- 
gration (data not shown). Thus a5, despite its pres- 
ence on venous SMCs, is not necessary for their 
migration. 
oLv[~3 integrin. We next investigated the et~Ect 
of a blocking antibody to the c~v[33 integrin on SMC 
migration. The av[33 integrin antibody (clone 
LM609) recognizes the integrin heterodimer rather 
than individual subunits. This antibody, at a dilution 
of 1:100, did not inhibit chemotaxis or haptotaxis to 
ECM proteins, including vitronectin (Fig. 5). How- 
ever, the ~v[33 integrin antibody significantly inhib- 
ited SMC chemotaxis nduced by PDGF-BB (53% -+ 
9% of control) and AB (61% -+ 5% of control; Fig. 5). 
In preliminary studies we demonstrated that the 
addition ofnonspecific mouse immunoglobulin G to 
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Fig. 4. Effects of~5 integrin antibody on SMC migration 
induced by ECM proteins and PDGF-BB. Chemotaxis of 
human SMCs incubated with collagen I (CNI; 1 b~g/ml), 
collagen IV (CNIV; 1 btg/ml), laminin (LN; 20 I~g/ml), 
fibronectin (FN; 20 i~g/ml), vitronectin (VN; 20 b~g/ml) 
and PDGF-BB (5 ng/ml), with (hatched bar) and without 
(filled bar) antibody to the c~5 subunit (dilution 1:1500). 
Results are expressed as a percentage of stimulated con- 
trol _+ SD. Experiments were performed in triplicate and 
repeated in multiple cell lines. Data from a representative 
experiment are shown. 
the upper chamber had no effect on chemotaxis or 
haptotaxis of  SMC to PDGF or the matrix proteins. 
DISCUSSION 
Vascular SMCs normally reside within the media 
of the vessel wall, and at the time of  arterial injury are 
influenced by surrounding matrix proteins. The pro- 
cess of intimal hyperplasia requires that SMCs mi- 
grate from the media into the intimal layer, and as a 
consequence these cells traverse the basement mem- 
brane, which is also composed of ECM proteins. We 
have recently demonstrated that matrix proteins di- 
rectly influence SMCs by promoting both chemo- 
taxis and haptotaxis,  The purpose of this investiga- 
tion is to further define how these proteins interact 
with SMCs to produce this migratoT T response. 
Integrins serve as receptors for ECM proteins. 
They arc transmembrane proteins with an extracellu- 
lar ligand-binding domain, an intramembranous do: 
main, and a cytoplasmic tail that mediates intracellu- 
lar responses. 6 Wc postulated that integrins might 
mediate the chemotactic stimulus provided by ECM 
proteins. We also queried whether migration in- 
duced by the potent growth factor agonist, PDGF, 
might also require activation of integrin receptors. 
Because previous reports have suggested that the 
intcgrin subunits and their functions vary between 
cell types, these studies were performed with SMC 
1501 
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Fig. 5. Effects ofc~v]33 integrin antibody on SMC migra- 
tion induced by ECM proteins and PDGF-BB. Chemo- 
taxis of human SMCs incubated with collagen I (CNI; 
1 ~g/ml), collagen IV (CNIV; 1 ~g/ml), laminin (LN; 
20 Ixg/ml), fibronectin (FN; 20 ~g/ml), vitronectin (VN; 
20 Ixg/ml) and PDGF-BB (5 ng/ml), with (hatched bar) 
and without (filled bar) antibody to the c~v[33 integrin 
(dilution, 1:100). Results are expressed as a percentage of
stimulated control _+ SD. Experiments were performed in
triplicate and repeated in multiple cell lines. Data from a 
representative experiment are shown. *p < 0.05 compared 
with control specimen. 
derived from human saphenous vein because of the 
relevance of this cell to the hyperplastic response that 
follows bypass grafting with autogenous vein. 
We evaluated three subunits and one integrin. 
Although there are at least 24 subunits and 20 inte- 
grin combinations, 8 we chose these four because of 
previous tudies that demonstrated their existence in 
arterial SMC. With appropriate antibodies, we were 
able to identify the ~2, c~5, and [31 subunits and the 
~v[33 integrin in human venous SMCs. The pattern 
of staining was similar for all three subunits. Proteins 
were distributed evenly throughout the SMC, with 
some increase in concentration atthe cell margins. In 
some cells, particularly those with migrating pheno- 
types, there was increased antibody staining in cellu- 
lar extensions or lamellipodia. In initial studies, we 
were not able to identify the c~v[33 antibody in our 
venous SMCs. This protein could be identified only 
after permeabilization of cells with Triton X-100. 
This was surprising because the antibody to ~v[33 is 
raised to the extracellular domain of this integrin. We 
surmise that the ~v[33 integrin is confined to the 
basal surface of these cells, which is inaccessible to 
the antibody during routine staining without perme- 
ablization. The significance of  this unusual distribu- 
tion of  the c~v[33 integrin is unclear. 
Of the integrins and subunits tested, [31 and ~2 
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appear to be the most critical for matrix protein- 
induced SMC chemotaxis and haptotaxis. Because 
the ~2 subunit combines only with the [31 protein to 
form the a2131 dimer, these data suggest hat a2131 
integrin is essential for SMC migration. Data from 
two previous studies have suggested an important 
role for the [31 subunit in SMC chemotaxis. 9,~° 
However, in both studies aortic SMCs were evalu- 
ated and PDGF was used as the only agonist. This 
study extends these previous observations regarding 
the [31 subunit o SMC derived from human saphe- 
nous vein. We have also found the [31 subunit o be 
critically necessary for SMC migration induced by 
ECM proteins. Interestingly, Sldnner et al. 9 found 
c~2131 to be present in cultured SMCs but not in 
freshly harvested cells. These authors postulated that 
expression of c~2 [31 might occur only in response to a 
stimulus for intimal hyperplasia, thus facilitating mi- 
gration of SMCs from the media to the neointimal 
space. 
The aS subunit was identified in SMCs; however, 
inhibition of this subunit had no effect on SMC 
chemotaxis. The aS subunit combines only with [31 
to form the ot5131 integrin. 15 Thus the ci5131 integtin 
must have a function in venous SMCs other than to 
facilitate migration. The absence of an effect ofc~5131 
inhibition on fibronectin-induced migration is sur- 
prising because this integrin has been described in 
many cells as the "fibronectin receptor." Other in- 
vestigators have shown that the antibody used in 
these studies, in the same dilutions, recognizes the 
c~5 subunit and inhibits fibronectin-induced activity 
in platelets, lymphocytes, and fibroblasts)  There are 
two possible explanations for our disparate findings. 
The physiologic responses mediated by integrin re- 
ceptors can vary from cell to cell, and thus in human 
venous SMCs o~5131 may not be the "fibronectin 
receptor," or at least the receptor that mediates mi- 
gration to fibronectin. Alternatively, but less likely, 
blocking the c~5 subunit may not be sutficient o 
inhibit attachment of fibronectin to the a5131 inte- 
grin as well as subsequent activation of the signal for 
migration. I f  this were true, it might be surmised that 
even though the a5131 receptor recognizes fibronec- 
tin, activation of only the [31 component is necessary 
to initiate the signaling cascade that leads to fi- 
bronectin-induced migration. 
The ~v[33 intcgrin does not appear to be neces- 
salt for the migratory response that results when 
SMCs are stimulated with matrix proteins. However, 
PDGF, which is a potent stimulus for intimal hyper- 
plasia and also an agonist of SMC migration, is at 
least in part reliant on this integrin. The results of 
previous tudies have been conflicting regarding the 
presence of cw[33 in SMCs and its physiologic role. 
Skinner et al. 9 were not able to identify the ~v[33 
integrin in an arterial SMC line, whereas Choi and 
coworkers n not only identified this integrin in rabbit 
SMCs but found that an inhibitory antibody mark- 
edly suppressed SMC migration in vitro. These in- 
vestigators found, in addition, that a protein that 
blocked c~v[33 inhibited intimal hyperplasia in an in 
vivo rabbit model. 
None of the subunits or integrins tested appears 
to be required for migration of venous SMCs to 
vitronectin. This is surprising because the cw[33 sub- 
unit has been identified in many other cell types as 
the vitronectin receptor) 6a7 This finding raises the 
question as to whether the antibody used in these 
experiments i  capable of inhibiting the ~v[33 inte- 
grin. This antibody, which has been raised to the 
extracellular domain of ~v[33, has been previously 
shown to bind to and inhibit its receptor. 16q8 In our 
own studies with human saphenous vein SMCs, irn- 
munofluorescence staining using this antibody has 
allowed the cw[33 integrin to be localized on the 
surface of venous SMCs. Finally, coincubation of this 
antibody with SMCs significantly inhibited their che- 
motaxis to PDGF, proving that at least for one ago- 
nist this antibody can effectively inhibit the integrin 
receptor. Because vitronectin provides achemotactic 
stimulus for human venous SMCs and because vitro- 
nectin affects SMCs at the time of arterial in jury ,  19 we 
conclude that a subunit or integrin other than [31, 
R2, ~5, or Rv[33 must mediate vitronectin's migra- 
tory effect. 
From our data we can make an additional inter- 
esting observation. The relative importance of the 
various integrins and their ability to facilitate SMC 
migration varies with each stimulus. For example, 
collagen I and laminin arc almost completely reliant 
on the [31 subunit for their chemotactic effect, 
whereas the [31 subunit is much less critical for mi- 
gration induced by collagen IV and fibronectin. The 
pattern is completely different for the c~2 subunit, 
which is necessary for chemotaxis to collagen I and 
IV and laminin (albeit less so than for the [31 sub- 
unit), whereas in repeated assays this subunit was not 
necessary for chemotaxis to fibronectin. None of 
these integrins or subunits are required for vitronec- 
tin-induced migration, and the array of integrins 
necessary for PDGF-induced migration is distinct 
from than that of the matrix proteins. Leavesley et 
al) 8 made similar observations in human arterial en- 
dothelial cells. The av[33 was essential for vitronec- 
tin-induced migration, whereas chemotaxis of endo- 
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thelial cells to collagen type I was reliant on the e~2131 
integrin. Observations regarding the specificity of 
matrix proteins and integrin receptors have been 
frequently made in other cell types, to the extent hat 
certain integrins have been termed "fibronectin re- 
ceptors" or "vitronectin receptors." However, it has 
become increasingly clear that the importance or 
functional consequence of an integrin varies not just 
with the stimulus but also with the cell type. The 
relationship between integrins and matrix proteins 
demonstrated in one cell cannot be extended to 
another cell. 
The necessity of integrins for PDGF-induced mi- 
gration is interesting and leads to the hypotheses that 
the two receptors must in some manner interact 
before migration can occur. Our data reveal that 
both the 131 subunit and the av133 integrin are re- 
quired for migration by PDGF. It has been postu- 
lated that there is "cross-talk" between PDGF and 
integrin receptors, especially the 13 subunit of  inte- 
grin receptor. This interaction may occur at the re- 
ceptor level, but it is more probable that this interde- 
pendence may be at the level of  the signaling 
cascades that follow ligand binding to both recep- 
tors. It has been recently demonstrated that binding 
of extracellular proteins to integrin receptors can 
activate a series of signaling pathways that are similar 
to those activated by growth factor receptors. 2°-22 
Examples of signaling proteins that are activated by 
both include focal adhesion kinase, 23 mitogen-acti- 
vated protein kinase, 24 phosphatidylinositol 3-ki- 
nase, 25-27 and phosphatidylinositol bisphosphate. 22 
The nature and specific location of this receptor 
"cross-talk" remains elusive. An alternative xplana- 
tion for our finding, that an integrin receptor is 
required for growth factor-induced migration, is 
that PDGF increases expression and production of a 
matrix protein (such as osteopontin) that then facili- 
tates migration through its integrin receptor. Thus 
the ability of PDGF to stimulate migration may in 
part be mediated through secretion of  ECM pro- 
teins. 
We have studied the effect of blocking integrins 
on both SMC chemotaxis (directed migration to- 
ward a soluble protein) and haptotaxis (directed mi- 
gration toward an insoluble matrix protein). Both 
stimuli can produce in SMC migration; however, 
haptotaxis appears to be the most potent of the two 
mechanisms. These two stimuli for migration appear 
to affect the cell in distinct ways and can activate 
different signaling pathways. We postulated that the 
integrins used by these migratory stimuli might also 
differ. However, we found that the pattern of the 
integrin involvement was identical for both hapto- 
taxis and chemotaxis. 
CONCLUSION 
We have identified the a2, ~5 and 131 subunits 
and the otv133 integrin in SMCs derived from human 
saphenous vein. All of  these proteins, with the excep- 
tion of the a5 subunit, appear to be at least partially 
necessary for SMC chemotaxis and haptotaxis. The 
131 subunit facilitates migration of both matrix pro- 
teins and PDGF, whereas the av133 integrin is only 
necessary for chemotaxis to PDGF. Because SMC 
migration is an essential part of the hyperplastic pro- 
cess, it is reasonable to assume that measures de- 
signed to suppress migration might retard or inhibit 
intimal hyperplasia. Such control might bc achieved 
through the design of proteins that inhibit the inte- 
grin function. 
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DISCUSSION 
Dr. Bauer E. Sumpio (New Haven, Conn.). I have 
two questions to ask. 
First, is there any difference in the distribution of inte- 
grins in SMCs from different sources? 
Second, you were able to block PDGF B stimulus with 
an antibody to integrins, and again as you suggested in 
your conclusions, this indicates that there is cross-talk 
between receptors on the surface and events that are occur- 
ring at the bottom of the cell in the focal adhesion plaques. 
On the basis of your results and the work that is currently 
going on in your laboratory, would you care to speculate 
where this interaction might occur and which part of the 
signal cascade is involved? Is this occurring in the nucleus 
or are there cytoplasmic protein interactions when these 
two systems are stimulated? 
Dr. Hiroyuki Itoh. Thank you very much, Dr. Sum- 
pio. Regarding the first question about he distribution of 
integrins in vascular SMCs, we have not studied cells other 
than those derived from human saphenous vein. However, 
there is evidence in the literature that differences do exist. 
Regarding the second question, it has been recently 
demonstrated that binding of extracellular p oteins to in- 
tegrin receptors can activate a series of signaling pathways 
that are similar to those activated by growth factor recep- 
tors. Examples of signaling proteins that are activated by 
both receptors include focal adhesion kinase, mitogen- 
activated protein kinase, phosphatidylinositol 3-kinase, and 
phosphatidylinositol biphosphate. It is possible that there 
may be cross-talk at any one of the points. 
Dr. Gary Nackman (Hanover, N.H.). I was intrigued 
by your finding that the antibody against the c~5 subunit or 
the ~5133 subunit did inhibit the vitronectin-stimulated 
chemotaxis, given that others have found that vitronectin 
probably is using the ~5133 integrin as a receptor. 
Dr. Itoh. You mean ~vJ33? 
Dr. Nackman. e~5133 has been shown by other investi- 
gators to work through vitronectin, and TGF-[3 has been 
demonstrated to upregulate that integrin, so I wondered 
why you didn't hink your antibody worked against vitro- 
nectin here but it worked with PDGF. 
Dr. Itoh. Thank you so much. The ~v[33 integrin is 
traditionally thought to be the vitronectin receptor, and we 
were surprised to find that an antibody to this receptor did 
not interfere with SMC migration in response to vitronec- 
tin. However, this finding serves to underscore the fact that 
the integrin behavior differs with each cell. It is possible 
that that c~v~3 integrin is not the vitronectin receptor for 
vascular SMCs. 
